Download the exact captured file
---
name: academic-biotechnology-bioprocesses
description: "Specializes in Biotechnology, Bioprocess Engineering, Industrial Bioreactors, and Recombinant DNA Technology building on Bioprocess Engineering Principles (Pauline M. Doran), Bioprocess Engineering (Shuler, Kargi, DeLisle), and Biotecnologia Industrial (Schmidell et al.). Covers Kinetic Modeling of Cell Growth (Monod, Luedeking-Piret), Hydrodynamics and Mass/Energy Balances in Bioreactors (STR, Airlift, Bubble Column, Single-Use SUBs), Volumetric Oxygen Transfer Coefficient (kLa), Downstream Purification Operations (Tangential Flow Filtration TFF, Affinity/IEX/HIC Chromatography, Lyophilization), Enzymology (Michaelis-Menten, Eadie-Hofstee), Therapeutic Product and Monoclonal Antibody (mAb) Technology, GLP (Good Laboratory Practice / NIT-DICLA-035), Biosafety (NB-1 to NB-4, CTNBio/ANVISA), and Biological Effluent Treatment."
---
# Biotechnology and Bioprocess Engineering (Doran & Shuler)
This skill establishes the kinetic, mathematical, and operational foundations for large-scale cultivation of microorganisms, plant, and mammalian cells, bioreactor sizing and automation, downstream recovery and purification, and compliance with biosafety and biopharmaceutical quality regulations.
---
## 🦠 1. Microbial Kinetics and Cell Growth Modeling
### 1.1 Monod Model and Growth Phases
The specific cell growth rate $\mu$ ($h^{-1}$) as a function of the limiting substrate concentration $S$ ($g/L$):
$$\mu = \mu_{max} \frac{S}{K_s + S}$$
where $\mu_{max}$ is the maximum growth rate and $K_s$ is the substrate affinity constant (the concentration at which $\mu = \frac{\mu_{max}}{2}$).
- **Biomass Variation ($X$) and Substrate Consumption ($S$) in Batch**:
$$\frac{dX}{dt} = \mu X - k_d X$$
$$\frac{dS}{dt} = -\frac{\mu X}{Y_{X/S}} - m_s X$$
where $Y_{X/S}$ is a growth-associated biomass yield and $m_s$ is the cell maintenance coefficient ($g_{subs}/g_{bio} \cdot h$). This expression assumes substrate use scales with gross growth $\mu X$; define and fit the yield consistently with the chosen biomass and decay model.
### 1.2 Product Formation Kinetics (Luedeking-Piret)
The product formation rate $q_p = \frac{1}{X}\frac{dP}{dt}$ correlates with growth and maintenance:
$$q_p = \alpha \mu + \beta \implies \frac{dP}{dt} = \alpha \mu X + \beta X$$
Here $\mu$ is the gross specific growth rate defined above. When $k_d$ is nonzero, $\mu X$ is not the net biomass derivative; substituting $dX/dt$ changes the model and requires a different definition of the growth-associated term.
- **Product Classification**:
1. **Growth-Associated ($\beta \approx 0$)**: E.g., ethanol, lactic acid.
2. **Non-Growth-Associated ($\alpha \approx 0$)**: E.g., secondary antibiotics, idiolytic metabolites in the stationary phase.
3. **Mixed / Partially Associated ($\alpha > 0, \beta > 0$)**: E.g., citric acid, induced enzymes.
---
## ⚗️ 2. Bioreactor Typology, Hydrodynamics, and Sizing
```
Classification of Industrial Bioreactors:
├── Mechanically Stirred Tank (STR - Stirred Tank Reactor):
│ ├── Rushton Impellers (radial flow - high gas dispersion)
│ ├── Hydrofoil/Pitch-Blade Impellers (axial flow - low shear)
│ └── Baffles for vortex suppression
├── Pneumatically Agitated:
│ ├── Airlift (with internal circulation via a concentric tube, or external)
│ └── Bubble Column
├── Fixed Bed and Fluidized Bed: Immobilized cells and enzymes
└── Single-Use Bioreactors (SUBs):
├── Multilayer polymeric bags (PE/EVOH Bags)
├── Wave/Rocking Bioreactors
└── Single-use stirred bioreactors (disposable STR up to 2,000 L)
```
### 2.1 Volumetric Oxygen Transfer Coefficient ($k_L a$)
Oxygen supply is the fundamental bottleneck in aerobic bioprocesses:
$$OTR = k_L a (C^* - C_L)$$
where $OTR$ is the Oxygen Transfer Rate ($mmol \, O_2 / L \cdot h$), $k_L a$ is the overall volumetric coefficient ($h^{-1}$), $C^*$ is the oxygen solubility at saturation, and $C_L$ is the dissolved oxygen in the medium.
- **Dynamic Balance for Experimental Determination of $k_L a$ (Dynamic Gassing-in / Degassing Method)**:
$$\frac{dC_L}{dt} = k_L a (C^* - C_L) - OUR$$
where $OUR = q_{O2} X$ is the cellular Oxygen Uptake Rate.
### 2.2 Empirical Power and Scale Correlation (Van't Riet)
For aerated stirred vessels in aqueous medium:
$$k_L a = C \left(\frac{P_g}{V}\right)^\alpha (v_s)^\beta$$
where $\frac{P_g}{V}$ is the power dissipated per unit volume under aeration ($W/m^3$) and $v_s$ is the superficial gas velocity ($m/s$).
---
## 🧪 3. Downstream Unit Operations of Purification
```mermaid
flowchart TD
A["Raw Fermented Broth"] --> B["1. Solid-Liquid Separation (Continuous Centrifugation / Tangential Microfiltration TFF)"]
B --> C{"Intracellular Product?"}
C -- Yes --> D["Cell Disruption (High-Pressure Homogenizer / Bead Mill)"]
C -- No --> E["2. Primary Concentration (Ultrafiltration with 10-100 kDa UF Membranes)"]
D --> E
E --> F["3. Chromatographic Capture and Purification"]
F --> G["Affinity Chromatography (e.g., Protein A for mAbs)"]
G --> H["Ion-Exchange Chromatography (IEX - Q/SP Sepharose)"]
H --> I["Hydrophobic Interaction Chromatography (HIC) / Size Exclusion (SEC)"]
I --> J["4. Polishing and Final Formulation (Viral Nanofiltration + Lyophilization / Spray Dryer Drying)"]
```
### 3.1 Tangential Flow Filtration (TFF) Theory
The permeate flux $J$ ($L/m^2 \cdot h$) through the ultrafiltration membrane under concentration polarization:
$$J = k \ln\left( \frac{C_m - C_p}{C_b - C_p} \right)$$
where $k$ is the mass transfer coefficient, $C_m$ is the concentration at the membrane surface, $C_b$ is the concentration in the bulk fluid, and $C_p$ is the concentration in the permeate.
---
## 🧬 4. Molecular Biology, Enzymology, and Recombinant DNA
### 4.1 Michaelis-Menten Enzyme Kinetics and Inhibition
Initial enzyme reaction velocity $v_0$:
$$v_0 = \frac{V_{max} [S]}{K_m + [S]}$$
- **Lineweaver-Burk Linear Transformation (Double Reciprocal)**:
$$\frac{1}{v_0} = \frac{K_m}{V_{max}} \frac{1}{[S]} + \frac{1}{V_{max}}$$
- **Competitive Inhibition**: $K_{m,app} = K_m \left(1 + \frac{[I]}{K_i}\right)$, $V_{max}$ unchanged.
- **Non-Competitive Inhibition**: $V_{max,app} = \frac{V_{max}}{1 + [I]/K_i}$, $K_m$ unchanged.
### 4.2 Recombinant DNA Technology and Expression
- **Plasmid Vector Design**: Strong, regulatable promoters (T7, tac, pGAP for *Pichia pastoris*), selection markers (antibiotic resistance), multiple cloning sites (MCS), and purification tags (6xHis His-tag, GST, FLAG).
- **Host Expression Systems**:
- *Escherichia coli*: High yield, no complex glycosylation, inclusion body formation.
- *Pichia pastoris / Saccharomyces cerevisiae*: Initial eukaryotic glycosylation, efficient secretion.
- CHO cells (Chinese Hamster Ovary): Gold standard for human biopharmaceuticals and monoclonal antibodies with authentic complex human glycosylation.
---
## 🛡️ 5. Good Practices, Biosafety, and Regulatory Framework
| Biosafety Level | Biological Agents | Containment Barriers & Requirements |
| :--- | :--- | :--- |
| **NB-1** | Well-characterized microorganisms that do not cause disease in healthy adult humans (e.g., *E. coli* K12, *S. cerevisiae*). | Open bench, daily decontamination, lab coat and gloves. |
| **NB-2** | Agents associated with human disease of moderate severity, risk of inoculation and ingestion (e.g., *Staphylococcus aureus*, HBV). | Class II A2/B2 Biological Safety Cabinet, accessible autoclave, access control. |
| **NB-3** | Indigenous or exotic agents with respiratory transmission potential that can cause serious/lethal disease (e.g., *Mycobacterium tuberculosis*, SARS-CoV-2). | Continuous negative differential pressure, exhaust air with double HEPA filtration, interlocked-door airlocks. |
| **NB-4** | Agents of high individual and community risk, with no available treatment or vaccine (e.g., Ebola, Marburg viruses). | Pressurized suits with self-contained air supply, maximum absolute isolation containment. |
- **Legal Framework in Brazil**:
- **CTNBio (National Technical Commission on Biosafety)**: Federal Law No. 11,105/2005 (GMO Biosafety Law) and the Biosafety Quality Certificate (CQB).
- **ANVISA**: RDC No. 658/2022 (General GMP Guidelines for Medicines), RDC No. 166/2017 (Validation of Analytical Methods), and RDC No. 55/2010 (Registration of Biological Products).
- **Inmetro / NIT-DICLA-035**: Accreditation of assays under Good Laboratory Practice (GLP/OECD) Principles.